These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 23175838)

  • 1. The complex PrP(c)-Fyn couples human oligomeric Aβ with pathological tau changes in Alzheimer's disease.
    Larson M; Sherman MA; Amar F; Nuvolone M; Schneider JA; Bennett DA; Aguzzi A; Lesné SE
    J Neurosci; 2012 Nov; 32(47):16857-71a. PubMed ID: 23175838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons.
    Um JW; Nygaard HB; Heiss JK; Kostylev MA; Stagi M; Vortmeyer A; Wisniewski T; Gunther EC; Strittmatter SM
    Nat Neurosci; 2012 Sep; 15(9):1227-35. PubMed ID: 22820466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alzheimer's amyloid-β oligomers rescue cellular prion protein induced tau reduction via the Fyn pathway.
    Chen RJ; Chang WW; Lin YC; Cheng PL; Chen YR
    ACS Chem Neurosci; 2013 Sep; 4(9):1287-96. PubMed ID: 23805846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatodendritic accumulation of Tau in Alzheimer's disease is promoted by Fyn-mediated local protein translation.
    Li C; Götz J
    EMBO J; 2017 Nov; 36(21):3120-3138. PubMed ID: 28864542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease.
    Roberson ED; Halabisky B; Yoo JW; Yao J; Chin J; Yan F; Wu T; Hamto P; Devidze N; Yu GQ; Palop JJ; Noebels JL; Mucke L
    J Neurosci; 2011 Jan; 31(2):700-11. PubMed ID: 21228179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptide aptamer targeting Aβ-PrP-Fyn axis reduces Alzheimer's disease pathologies in 5XFAD transgenic mouse model.
    Ali T; Klein AN; Vu A; Arifin MI; Hannaoui S; Gilch S
    Cell Mol Life Sci; 2023 May; 80(6):139. PubMed ID: 37149826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer aβ oligomer bound to cellular prion protein.
    Um JW; Kaufman AC; Kostylev M; Heiss JK; Stagi M; Takahashi H; Kerrisk ME; Vortmeyer A; Wisniewski T; Koleske AJ; Gunther EC; Nygaard HB; Strittmatter SM
    Neuron; 2013 Sep; 79(5):887-902. PubMed ID: 24012003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble Conformers of Aβ and Tau Alter Selective Proteins Governing Axonal Transport.
    Sherman MA; LaCroix M; Amar F; Larson ME; Forster C; Aguzzi A; Bennett DA; Ramsden M; Lesné SE
    J Neurosci; 2016 Sep; 36(37):9647-58. PubMed ID: 27629715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amyloid-β induced signaling by cellular prion protein and Fyn kinase in Alzheimer disease.
    Um JW; Strittmatter SM
    Prion; 2013; 7(1):37-41. PubMed ID: 22987042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-106b inhibits tau phosphorylation at Tyr18 by targeting Fyn in a model of Alzheimer's disease.
    Liu W; Zhao J; Lu G
    Biochem Biophys Res Commun; 2016 Sep; 478(2):852-7. PubMed ID: 27520374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tau reduction prevents Aβ-induced axonal transport deficits by blocking activation of GSK3β.
    Vossel KA; Xu JC; Fomenko V; Miyamoto T; Suberbielle E; Knox JA; Ho K; Kim DH; Yu GQ; Mucke L
    J Cell Biol; 2015 May; 209(3):419-33. PubMed ID: 25963821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse.
    Chung E; Ji Y; Sun Y; Kascsak RJ; Kascsak RB; Mehta PD; Strittmatter SM; Wisniewski T
    BMC Neurosci; 2010 Oct; 11():130. PubMed ID: 20946660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aβ-induced acceleration of Alzheimer-related τ-pathology spreading and its association with prion protein.
    Gomes LA; Hipp SA; Rijal Upadhaya A; Balakrishnan K; Ospitalieri S; Koper MJ; Largo-Barrientos P; Uytterhoeven V; Reichwald J; Rabe S; Vandenberghe R; von Arnim CAF; Tousseyn T; Feederle R; Giudici C; Willem M; Staufenbiel M; Thal DR
    Acta Neuropathol; 2019 Dec; 138(6):913-941. PubMed ID: 31414210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fyn knock-down increases Aβ, decreases phospho-tau, and worsens spatial learning in 3×Tg-AD mice.
    Minami SS; Clifford TG; Hoe HS; Matsuoka Y; Rebeck GW
    Neurobiol Aging; 2012 Apr; 33(4):825.e15-24. PubMed ID: 21741124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overcoming barriers and thresholds - signaling of oligomeric Aβ through the prion protein to Fyn.
    Wang H; Ren CH; Gunawardana CG; Schmitt-Ulms G
    Mol Neurodegener; 2013 Jul; 8():24. PubMed ID: 23856335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tau acts as a mediator for Alzheimer's disease-related synaptic deficits.
    Liao D; Miller EC; Teravskis PJ
    Eur J Neurosci; 2014 Apr; 39(7):1202-13. PubMed ID: 24712999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pseudophosphorylation of Tau at distinct epitopes or the presence of the P301L mutation targets the microtubule-associated protein Tau to dendritic spines.
    Xia D; Li C; Götz J
    Biochim Biophys Acta; 2015 May; 1852(5):913-24. PubMed ID: 25558816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fyn depletion ameliorates tau
    Liu G; Fiock KL; Levites Y; Golde TE; Hefti MM; Lee G
    Acta Neuropathol Commun; 2020 Jul; 8(1):108. PubMed ID: 32665013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fyn Kinase Controls Tau Aggregation In Vivo.
    Briner A; Götz J; Polanco JC
    Cell Rep; 2020 Aug; 32(7):108045. PubMed ID: 32814048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular prion protein as a therapeutic target in Alzheimer's disease.
    Laurén J
    J Alzheimers Dis; 2014; 38(2):227-44. PubMed ID: 23948943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.